Fibromyalgia/Pain

Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
Dr. John Cush @RheumNow( View Tweet )
#OP0159 #EULAR2026 Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow https://t.co/qMQbkiMCwX

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
Does #RA accelerate age-related functional decline in older adults? STAR study (n=421, age 55-85): RA with worse HAQ, grip strength, but aging's effect on function similar in RA vs controls. Geriatric syndromes like sarcopenia may matter more than RA @RheumNow #EULAR2026 POS0360

Jiha Lee @JihaRheum( View Tweet )

Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs? RISE registry Retrospective N=60,206 Tirzepatide: lost 8% Semaglutide: list 6% At 12 months PsA had the highest usage OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
Machine learning identifies a “vulnerable” phenotype in older RA patients n=275 -51% “vulnerable” -Worse grip strength, gait speed & SARC-F -Higher disability (HAQ 1.56 vs 0.64) -More fatigue, poorer QoL -Higher DAS28 despite greater biologic exposure Suggests we should assess https://t.co/bv1FbTxGKR

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Failure to achieve early remission RA asso w/ non-inflammatory pain NORD-STAR 526 early RA pts) no remission at 24 wks increased risk of 48wk • unacceptable pain (OR ~6) • refractory pain (OR ~6) • fibromyalgic RA (OR ~16) Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX

Links:

Jiha Lee @JihaRheum( View Tweet )
EULAR flags

Day 3 EULAR Report

Jack Cush, MD

Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.

Read Article
What does remission look like for people living with PsA? Much more than the absence of swollen joints Absence of pain Skin management Ability to resume daily activities Sustained over time A definition not always reflected in our disease activity scores #POS0294 #EULAR2026 https://t.co/VCnMGAOVYm

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
PET-derived parameters in #PsA correlated with DAPSA, CRP and patient pain. Angiogenesis imaging may be a complementary biomarker of overall disease burden Abstr#OP068 #EULAR2026 #Imaging

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
đź”® Can polygenic risk scores predict PsA timing in psoriasis? Another GWAS study (n=703) says YES! 70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years #POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
@RheumNow HOT #Obesity session (7) 📢A call for action Current RMD treatments ignore obesity: They all target immune response but miss the metabolic-inflammatory loop Breaking that cycle may be the missing piece Obesity must be part of every rheumatology plan #EULAR2026 @rheumnow

Nelly ZIADE 🍀 @Nellziade( View Tweet )

Treatment for #lupus #brain #fog?! #small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR #memantine N=19 v #PBO N=25 showed more improvemt #EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7

Links:

Janet Pope @Janetbirdope( View Tweet )
ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score Potential adjunct tx for NPSLE? AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s

Links:

sheila @RHEUMarampa( View Tweet )
D2T RA shows a linked brain–psychology–immune signature Cohort D2T RA vs non-D2T RA vs HC 91% D2T RA Higher catastrophizing Higher pain sensitivity More emotion-focused coping strategies “Chronic pain-like” profile Associated with higher CNS related gene expression NRG1 https://t.co/nkQco73vqI

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow. Average age 28! 87%female, only 7 % with psychiatric referral! Retrospective 15 pts. https://t.co/241SE6O395

Links:

Bella Mehta @bella_mehta( View Tweet )
Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

pain.jpg

The pain that inflammation does not explain in SpA and PsA

Antoni Chan, MD, PhD

Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the

Read Article
🥗 Does diet improve PsA? DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts Weight loss drove outcomes OP070 #EULAR2026 @RheumNow https://t.co/k5y7bvDbDQ

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
This retrospective cohort of NPSLE pts showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI Pts w/ diffuse symptoms - normal MRI except brain atrophy Interesting to know how this can aid in future mgt strategies for NPSLE OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK

Links:

sheila @RHEUMarampa( View Tweet )
Curcumin in arthritis may have NSAID like clinical efficacy. But how? Metanalysis lays out the multiple potential effects for it to inhibit inflammatory signaling pathways (NF-κB, TNF-α, IL-1β, IL-6, COX-2, and PGE2) https://t.co/gSYVwpl41P https://t.co/0xZdyiF4QN

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
Goofy study of the month! (pub in JAMA!) RCT 170 adults w/ chronic LBP + MRI disc herniation found that amoxicillin-clavulanate, 500 mg/125 mg bid x 3 mos did not improve pain at 3 or 12 mos (vs PBO). Whatha... https://t.co/njrw6itAP8 https://t.co/CW2ssNPxf1

Links:

Dr. John Cush @RheumNow( View Tweet )
APR: Fibromyalgia Dr. Jack Cush reviews Fibromyalgia as part of the Advanced Practice Rheum video series. https://t.co/jq6dSXy6SU https://t.co/bDGRhhY2D9

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Advanced Practice Rheum

Fibromyalgia

Jack Cush, MD
APR fibro video cover
Dr. Jack Cush reviews fibromyalgia.
Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article

From DNA to PGA

David Pisetsky, MD, PhD
dna
I have been investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978. In this pursuit, I have followed the advice of my first division chief, Dr. Ralph Snyderman, a great academician.  Ralph told me to identify a research focus and make it mine. I think I have done reasonably well in my mission so you can imagine my surprise (and excitement) when, for the Lupus 2025 meeting in Toronto, I was asked to conduct a Meet the Professor session on the Type 1 & 2 model for SLE.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR 2025 Daily Podcasts Day3c
  • ACR 2025 Daily Podcasts Day3a
  • ACR 2025 Daily Podcasts Day2c
×